Glenmark, Shasun ink pact to develop drugs for US

Glenmark, Shasun ink pact to develop drugs for US Mumbai: GLENMARK Pharmaceuticals Ltd and Shasun Chemicals and Drugs Ltd have signed a pact for joint development, filing and marketing of 12 generic drugs for the US market. The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of about $8 billion. Under the agreement, Shasun will develop and license to Glenmark 12 generic products. Glenmark, in turn, will be responsible for filing the abbreviated new drug applications (ANDAs) and obtaining regulatory approval in the US market. Upon approval, Glenmark’s US subsidiary, Glenmark Read More


ˆ Back To Top